by davidweb1 | Jul 4, 2017 | PATENT INFRINGEMENT, Uncategorized
Phase III Biosimilar Clinical Trial & Infringement Threat does not Create Justiciable Case or Controversy: Biosimilars will require the Patent Dance In Sandoz Inc. v. Amgen Inc., the Federal Circuit upheld the district court decision dismissing Sandoz’s...
by davidweb1 | Jul 4, 2017 | PATENT INFRINGEMENT, Uncategorized
Commil v. Cisco: Whether a good-faith belief of invalidity negates the intent requirement for induced infringement On December 5, 2014, the Supreme Court granted certiorari in Commil USA v. Cisco Systems to decide whether a defendant’s good-faith belief of patent...
by davidweb1 | Jul 4, 2017 | PATENT, PATENT INFRINGEMENT, PATENT LITIGATION, Uncategorized
Teva v. Sandoz: The New Standard of Review In Claim Construction In Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., the Supreme Court addressed the question of what the standard of review should be for patent claim construction. In its decision on January 20, 2015,...
by davidweb1 | Jul 4, 2017 | INTELLECTUAL PROPERTY, LEGISLATION, PATENT, PATENT INFRINGEMENT, PATENT LITIGATION, Uncategorized
Sen. Grassley (R-IA) Introduces Patent Act of 2015 Today, Sen. Grassley of Iowa introduced a Senate Bill entitled “Protecting American Talent and Entrepreneurship Act of 2015” Among other things, the Bill is aimed at curbing perceived patent litigation abuses by...
by davidweb1 | Jul 4, 2017 | INTELLECTUAL PROPERTY, INTER PARTES REVIEW, IP LITIGATION, PATENT, PATENT INFRINGEMENT, PATENT LITIGATION, Uncategorized
Patent litigation is declining….or is it increasing? Pricewatherhouse Cooper’s 2015 Patent Litigation Study, entitled A change in patentee fortunes made several observations about the shifting state of patent litigation in the United States: That patent lawsuits...
